A survey study from the  ArthritisPower PPRN or CreakyJoints database shows that during the COVID-19 pandemic patient care was substantially affected in unforeseen ways. Data from the ArthritisPower Patient-Powered Research Network and CreakyJoints patient community were gathered by surveys of US patients with RA, PsA, AS, and SLE. 

JAMA has published the real-world reporting of mRNA vaccine side effects (reactogenicity) gathered from CDC V-safe Surveillance system and shows that local and systemic reactions were often mild and transient and most commonly seen during the first day following their second dose.

Total knee replacement (TKR) in obese patients with end-stage knee osteoarthritis appears to be a beneficial and cost-effective strategy for treating. The only potential limitation is a greater risk for adverse events in those with a body mass index (BMI) of 40 kg/m2 or greater.

No drug is FDA approved to manage the skin or joint complaints of systemic sclerosis (SSc); a recent metanalysis suggests that rituximab may improve skin score and disease activity indices (DAS, mRSS) while stabilizing organ involvement in SSc patients.